Remepy’s Hybridopa therapy for Parkinson’s, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies. A new San Diego

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

Last week at our biopharma and healthcare summit with the Financial Times, I was asked during one of our breaks when we’ll see the first

💉 Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20: The vaccine candidate, codenamed PF-07872412, produced higher geometric mean titers for serotype 3 than Pfizer’s approved